Cellular assays

Cell migration assays can be time-consuming and challenging, from identifying and ensuring assays are imaged at the appropriate time, to properly measuring wound closure. In this new App Note, discover the benefits of Evident’s CM cell culture monitors, which provide label-free, quantitative results, consistent results throughout your lab, and are cost-effective. Researchers at ACEL simplified […]

Cell migration assays can be time-consuming and challenging, from identifying and ensuring assays are imaged at the appropriate time, to properly measuring wound closure. Evident’s CM cell culture monitors provide label-free, quantitative results, consistent results throughout your lab, and are cost-effective. Researchers at ACEL simplified the cell migration process by using Evident’s CM cell culture […]

By DDW Editor Reece Armstrong A lot has already been said about the US Food and Drug Administration’s (FDA) Modernization Act 2.0 and for good reason. The decision by the Biden administration to end the federal requirement for drugs under development to be tested on animals represents a significant step forward for the life sciences sectors. The legislation […]

By Dr Karin Bottcher High content screening (HCS) has played a significant role in infectious disease research and drug discovery to date and can be a strong tool in the age of COVID-19 and beyond. With a focus on viral diseases, this article will describe how HCS has been used by laboratories around the world […]

The COVID-19 antiviral race: we’re all in this together By Uduak Grace Thomas In response to the COVID-19 pandemic, international scientists from academia and industry have pooled their expertise and resources to identify candidate compounds that inhibit the activity of the SARS-CoV-2 main protease, in order to develop a clinically effective antiviral. The aptly named […]

The CELL CULTURE innovations increasing drug discovery success By Helen Stewart-Miller and Abby George Volume 21 Issue 3 – Summer 2020 ‘Fail early, fail fast’ has been a mantra in the pharmaceutical industry for several years and directly impacts the overall strategy of many drug discovery and development programmes. Yet, despite the drive to fail […]

Collaborative Research Leads To New Understanding Of Biomarkers By Dr Max Ryadnov and Professor Jason Crain A new collaborative research paper sheds light on the way antibodies distinguish between different but closely related ‘biomarkers’ – in this case protein fragments which reveal information about the condition of the human body. This new understanding could enable […]

Guidelines & Recommendations For Analyzing and Interpreting GPCR Second Messenger Data Sponsored by CisBio The question of choosing which methods to use for analyte quantification (signal vs concentration determination, parameters, and format) continues to generate heated debates and divergent understanding. Today, there is still a communication gap between researchers depending on their field of expertise […]

Stem Cell Differentiation By Dr Lilian Hook Stem cells are extraordinary cells, capable of both self-renewal and differentiation to mature somatic cells in vivo and in vitro (1,2). They have many features and advantages which could revolutionise drug development and healthcare applications. Stem cells offer a limitless, consistent supply of physiologically relevant cells from validated […]

Phenotypic Drug Discovery With High Content Screening Sponsored by PerkinElmer Early drug discovery used to be conducted mainly in a target-agnostic fashion, focusing on qualitative readouts from a living system – cells, tissue, or organisms – and asking the question, did this entity affect the phenotype? Target Based or Phenotypic Screening? With the rise of […]

Targeting Energy Metabolism for Cancer Therapeutic Discovery using Agilent Seahorse XF Technology Sponsored by Agilent This white paper discusses targeting energy metabolism for cancer therapeutic discovery using Agilent Seahorse XF technology. Abstract Altered energy metabolism is now recognized as a driver in many diseases. In cancer research, significant advances have been made in defining druggable […]

Advanced Therapeutic Antibody Discovery with Multiplexed Screening Sponsored by Sartorius Antibody-based therapeutics are the fastest growing and most successful therapeutic modality for treating diseases such as cancer, cardiovascular disease, autoimmune disorders and infectious disease. It is predicted that by the year 2020 there will be 70 therapeutic antibodies on the market, generating revenue of $125 […]

Sphere Fluidics expands commercial operations to increase supply of Pico-Surf surfactant for droplet microfluidics. Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, today announced investment in the production and supply of its proprietary biocompatible surfactant, Pico-Surf™, for reliable and highly stable droplet generation and processing. Sphere Fluidics will […]

State-of-the art facility is home to the company’s next-generation, fully automated platform for drug discovery. Arctoris Ltd, the developer of the world’s first fully automated drug discovery platform, today opened the doors to its new global headquarters and state-of-the-art research and development (R&D) facility in Oxford, UK. Housing the company’s proprietary technology and providing space […]

A team of British and American scientists has discovered a way to slow the growth of breast cancer stem cells in the lab. The study led by Dr Bruno Simões and Professor Rob Clarke from The University of Manchester could eventually lead to combination drug therapies on previously untreatable breast cancers. Around three quarters of […]

Image: Joshua Coleman According to the Department of Health and Social Care (DHSC), pharmaceutical companies should stockpile six weeks’ worth of goods “to help ensure the continuity of supply of medical goods into and out of the UK”. In a letter to the industry Steve Oldfield, Chief Commercial Officer, acknowledges the impact of COVID-19 on the sector […]